2019 quarterly periods ended | ||||||||||||||||
March 31 | June 30 | September 30 | December 31 | |||||||||||||
Packaging | ||||||||||||||||
Net sales | $ | 88,840 | $ | 103,990 | $ | 105,480 | $ | 94,030 | ||||||||
Operating profit | $ | 17,640 | $ | 22,640 | $ | 19,740 | $ | 20,750 | ||||||||
Special Items(1) to consider in evaluating operating profit: | ||||||||||||||||
Reversal of a contingent deferred purchase price liability | — | — | — | (3,950 | ) | |||||||||||
Purchase accounting costs | 1,020 | 260 | — | — | ||||||||||||
Business restructuring and severance costs | — | — | 360 | 2,700 | ||||||||||||
Adjusted operating profit | $ | 18,660 | $ | 22,900 | $ | 20,100 | $ | 19,500 | ||||||||
Aerospace | ||||||||||||||||
Net sales | $ | 38,330 | $ | 42,240 | $ | 43,140 | $ | 41,130 | ||||||||
Operating profit | $ | 5,740 | $ | 7,010 | $ | 8,230 | $ | 7,420 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | 440 | — | — | — | ||||||||||||
Adjusted operating profit | $ | 6,180 | $ | 7,010 | $ | 8,230 | $ | 7,420 | ||||||||
Specialty Products | ||||||||||||||||
Net sales | $ | 94,120 | $ | 93,140 | $ | 88,210 | $ | 35,760 | ||||||||
Operating profit | $ | 10,860 | $ | 10,170 | $ | 8,400 | $ | 2,530 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | — | — | — | 200 | ||||||||||||
Adjusted operating profit | $ | 10,860 | $ | 10,170 | $ | 8,400 | $ | 2,730 | ||||||||
Corporate Expenses | ||||||||||||||||
Operating loss | $ | (8,390 | ) | $ | (8,710 | ) | $ | (7,680 | ) | $ | (9,910 | ) | ||||
Special Items to consider in evaluating operating loss: | ||||||||||||||||
M&A diligence and transaction costs | 1,120 | 700 | 700 | 1,440 | ||||||||||||
Adjusted operating loss | $ | (7,270 | ) | $ | (8,010 | ) | $ | (6,980 | ) | $ | (8,470 | ) | ||||
Total Company | ||||||||||||||||
Net sales | $ | 221,290 | $ | 239,370 | $ | 236,830 | $ | 170,920 | ||||||||
Operating profit | $ | 25,850 | $ | 31,110 | $ | 28,690 | $ | 20,790 | ||||||||
Total Special Items to consider in evaluating operating profit | 2,580 | 960 | 1,060 | 390 | ||||||||||||
Adjusted operating profit | $ | 28,430 | $ | 32,070 | $ | 29,750 | $ | 21,180 |
2019 quarterly periods ended | ||||||||||||||||
March 31 | June 30 | September 30 | December 31 | |||||||||||||
Aerospace - as previously reported | ||||||||||||||||
Net sales | $ | 38,330 | $ | 42,240 | $ | 43,140 | $ | 41,130 | ||||||||
Operating profit | $ | 5,740 | $ | 7,010 | $ | 8,230 | $ | 7,420 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | 440 | — | — | — | ||||||||||||
Adjusted operating profit | $ | 6,180 | $ | 7,010 | $ | 8,230 | $ | 7,420 | ||||||||
Aerospace - recast for segment change | ||||||||||||||||
Net sales | $ | 45,580 | $ | 49,510 | $ | 50,560 | $ | 48,460 | ||||||||
Operating profit | $ | 5,810 | $ | 7,650 | $ | 7,810 | $ | 7,680 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | 440 | — | — | — | ||||||||||||
Adjusted operating profit | $ | 6,250 | $ | 7,650 | $ | 7,810 | $ | 7,680 | ||||||||
Specialty Products - as previously reported | ||||||||||||||||
Net sales | $ | 94,120 | $ | 93,140 | $ | 88,210 | $ | 35,760 | ||||||||
Operating profit | $ | 10,860 | $ | 10,170 | $ | 8,400 | $ | 2,530 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | — | — | — | 200 | ||||||||||||
Adjusted operating profit | $ | 10,860 | $ | 10,170 | $ | 8,400 | $ | 2,730 | ||||||||
Specialty Products - recast for segment change | ||||||||||||||||
Net sales | $ | 86,870 | $ | 85,870 | $ | 80,790 | $ | 28,430 | ||||||||
Operating profit | $ | 10,790 | $ | 9,530 | $ | 8,820 | $ | 2,270 | ||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||
Business restructuring and severance costs | — | — | — | 200 | ||||||||||||
Adjusted operating profit | $ | 10,790 | $ | 9,530 | $ | 8,820 | $ | 2,470 |
2019 quarterly periods ended | ||||||||||||||||||||
March 31 | June 30 | September 30 | December 31 | Year ended December 31, 2019 | ||||||||||||||||
Packaging | ||||||||||||||||||||
Net sales | $ | 88,840 | $ | 103,990 | $ | 105,480 | $ | 94,030 | $ | 392,340 | ||||||||||
Operating profit | $ | 17,640 | $ | 22,640 | $ | 19,740 | $ | 20,750 | $ | 80,770 | ||||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||||||
Reversal of a contingent deferred purchase price liability | — | — | — | (3,950 | ) | (3,950 | ) | |||||||||||||
Purchase accounting costs | 1,020 | 260 | — | — | 1,280 | |||||||||||||||
Business restructuring and severance costs | — | — | 360 | 2,700 | 3,060 | |||||||||||||||
Adjusted operating profit | $ | 18,660 | $ | 22,900 | $ | 20,100 | $ | 19,500 | $ | 81,160 | ||||||||||
Aerospace | ||||||||||||||||||||
Net sales | $ | 45,580 | $ | 49,510 | $ | 50,560 | $ | 48,460 | $ | 194,110 | ||||||||||
Operating profit | $ | 5,810 | $ | 7,650 | $ | 7,810 | $ | 7,680 | $ | 28,950 | ||||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||||||
Business restructuring and severance costs | 440 | — | — | — | 440 | |||||||||||||||
Adjusted operating profit | $ | 6,250 | $ | 7,650 | $ | 7,810 | $ | 7,680 | $ | 29,390 | ||||||||||
Specialty Products | ||||||||||||||||||||
Net sales | $ | 38,950 | $ | 37,330 | $ | 32,370 | $ | 28,430 | $ | 137,080 | ||||||||||
Operating profit | $ | 4,700 | $ | 5,410 | $ | 3,620 | $ | 2,270 | $ | 16,000 | ||||||||||
Special Items to consider in evaluating operating profit: | ||||||||||||||||||||
Business restructuring and severance costs | — | — | — | 200 | 200 | |||||||||||||||
Adjusted operating profit | $ | 4,700 | $ | 5,410 | $ | 3,620 | $ | 2,470 | $ | 16,200 | ||||||||||
Corporate Expenses | ||||||||||||||||||||
Operating loss | $ | (8,350 | ) | $ | (8,640 | ) | $ | (7,600 | ) | $ | (9,910 | ) | $ | (34,500 | ) | |||||
Special Items to consider in evaluating operating loss: | ||||||||||||||||||||
M&A diligence and transaction costs | 1,120 | 700 | 700 | 1,440 | 3,960 | |||||||||||||||
Adjusted operating loss | $ | (7,230 | ) | $ | (7,940 | ) | $ | (6,900 | ) | $ | (8,470 | ) | $ | (30,540 | ) | |||||
Total Company | ||||||||||||||||||||
Net sales | $ | 173,370 | $ | 190,830 | $ | 188,410 | $ | 170,920 | $ | 723,530 | ||||||||||
Operating profit | $ | 19,800 | $ | 27,060 | $ | 23,570 | $ | 20,790 | $ | 91,220 | ||||||||||
Total Special Items to consider in evaluating operating profit | 2,580 | 960 | 1,060 | 390 | 4,990 | |||||||||||||||
Adjusted operating profit | $ | 22,380 | $ | 28,020 | $ | 24,630 | $ | 21,180 | $ | 96,210 |
2019 quarterly periods ended | ||||||||||||||||
March 31 | June 30 | September 30 | Nine months ended September 30, 2019 | |||||||||||||
Income from continuing operations, as previously reported | $ | 19,090 | $ | 22,020 | $ | 19,110 | $ | 60,220 | ||||||||
Special Items to consider in evaluating quality of income from continuing operations: | ||||||||||||||||
M&A diligence and transaction costs | 1,120 | 700 | 700 | 2,520 | ||||||||||||
Business restructuring and severance costs | 440 | — | 360 | 800 | ||||||||||||
Purchase accounting costs | 1,020 | 260 | — | 1,280 | ||||||||||||
Income tax effect of Special Items (1) | (560 | ) | (100 | ) | (200 | ) | (860 | ) | ||||||||
Adjusted income from continuing operations | $ | 21,110 | $ | 22,880 | $ | 19,970 | $ | 63,960 | ||||||||
2019 quarterly periods ended | ||||||||||||||||
March 31 | June 30 | September 30 | Nine months ended September 30, 2019 | |||||||||||||
Diluted earnings per share from continuing operations, as previously reported | $ | 0.42 | $ | 0.48 | $ | 0.42 | $ | 1.32 | ||||||||
Special Items to consider in evaluating quality of EPS from continuing operations: | ||||||||||||||||
M&A diligence and transaction costs | 0.02 | 0.01 | 0.01 | 0.05 | ||||||||||||
Business restructuring and severance costs | 0.01 | — | 0.01 | 0.02 | ||||||||||||
Purchase accounting costs | 0.02 | 0.01 | — | 0.03 | ||||||||||||
Income tax effect of Special Items (1) | (0.01 | ) | — | — | (0.02 | ) | ||||||||||
Adjusted diluted EPS from continuing operations | $ | 0.46 | $ | 0.50 | $ | 0.44 | $ | 1.40 | ||||||||
Weighted-average shares outstanding | 45,992,182 | 45,828,315 | 45,415,767 | 45,745,421 | ||||||||||||
Recast | As reported | |||||||||||||||||||
2019 quarterly periods ended | ||||||||||||||||||||
March 31 | June 30 | September 30 | December 31 | Year ended December 31, 2019 | ||||||||||||||||
Income from continuing operations | $ | 14,550 | $ | 18,720 | $ | 15,240 | $ | 13,430 | $ | 61,940 | ||||||||||
Special Items to consider in evaluating quality of income from continuing operations: | ||||||||||||||||||||
M&A diligence and transaction costs | 1,120 | 700 | 700 | 1,440 | 3,960 | |||||||||||||||
Business restructuring and severance costs | 440 | — | 360 | 2,900 | 3,700 | |||||||||||||||
Purchase accounting costs | 1,020 | 260 | — | — | 1,280 | |||||||||||||||
Reversal of a contingent deferred purchase price liability | — | — | — | (3,950 | ) | (3,950 | ) | |||||||||||||
Income tax effect of Special Items (1) | (560 | ) | (100 | ) | (200 | ) | 120 | (740 | ) | |||||||||||
Adjusted income from continuing operations | $ | 16,570 | $ | 19,580 | $ | 16,100 | $ | 13,940 | $ | 66,190 | ||||||||||
Recast | As reported | |||||||||||||||||||
2019 quarterly periods ended | ||||||||||||||||||||
March 31 | June 30 | September 30 | December 31 | Year ended December 31, 2019 | ||||||||||||||||
Diluted earnings per share from continuing operations | $ | 0.32 | $ | 0.41 | $ | 0.34 | $ | 0.30 | $ | 1.36 | ||||||||||
Special Items to consider in evaluating quality of EPS from continuing operations: | ||||||||||||||||||||
M&A diligence and transaction costs | 0.02 | 0.01 | 0.01 | 0.03 | 0.09 | |||||||||||||||
Business restructuring and severance costs | 0.01 | — | 0.01 | 0.07 | 0.08 | |||||||||||||||
Purchase accounting costs | 0.02 | 0.01 | — | — | 0.03 | |||||||||||||||
Reversal of a contingent deferred purchase price liability | — | — | — | (0.09 | ) | (0.09 | ) | |||||||||||||
Income tax effect of Special Items (1) | (0.01 | ) | — | — | — | (0.02 | ) | |||||||||||||
Adjusted diluted EPS from continuing operations | $ | 0.36 | $ | 0.43 | $ | 0.36 | $ | 0.31 | $ | 1.45 | ||||||||||
Weighted-average shares outstanding | 45,992,182 | 45,828,315 | 45,415,767 | 45,144,353 | 45,595,154 | |||||||||||||||